Reference health
Update on cardiotoxicity of anti‐cancer treatments
155/155 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
11 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 155 checked references that resolve
resolves10.1200/JCO.2005.05.827
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
resolves10.1186/1471-2407-10-337
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
resolves10.1016/j.repc.2012.11.002
Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção
resolves10.1161/CIRCULATIONAHA.109.895771
Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell Function
resolves10.1111/j.1365-2141.2005.05759.x
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
resolves10.1016/j.pharmthera.2009.10.002
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
resolves10.1200/JCO.2011.34.8987
Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group
resolves10.1159/000356850
Evaluation of Cardiotoxicity via Speckle-Tracking Echocardiography in Patients Treated with Anthracyclines
resolves10.1016/j.critrevonc.2013.02.007
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review
resolves10.1093/annonc/mdf108
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil
resolves10.1016/j.ctrv.2013.03.005
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors
resolves10.1200/JCO.1992.10.11.1795
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
resolves10.1002/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C
The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy
resolves10.1007/s00432-007-0250-9
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study
resolves10.1007/s00280-005-0178-1
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
resolves10.1056/NEJMoa071028
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
resolves10.1182/blood.V68.5.1114.1114
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor
resolves10.1200/JCO.1991.9.7.1215
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.
resolves10.1001/archinte.1981.00340060066015
Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy
resolves10.1016/S1083-8791(00)70043-7
Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer
resolves10.1016/S0022-5347(01)62232-8
HIGH RISK OF VASCULAR EVENTS IN PATIENTS WITH UROTHELIAL TRANSITIONAL CELL CARCINOMA TREATED WITH CISPLATIN BASED CHEMOTHERAPY
resolves10.1002/1097-0142(19930715)72:2<587::AID-CNCR2820720242>3.0.CO;2-V
Severe vascular toxicity associated with cisplatin-based chemotherapy
resolves10.1200/JCO.2000.18.8.1725
Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer
resolves10.1053/j.ajkd.2006.11.039
Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis
resolves10.1093/annonc/mdn637
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
resolves10.1634/theoncologist.2009-0252
Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?
resolves10.1345/aph.1H244
Angiotensin-Converting Enzyme Inhibitors for Bevacizumab-Induced Hypertension
resolves10.1093/jnci/djm086
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
resolves10.1634/theoncologist.2008-0137
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
resolves10.1200/JCO.2005.13.300
Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment
resolves10.4161/cc.7.12.6016
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells
resolves10.1200/JCO.2006.09.1611
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
resolves10.1016/S0025-6196(11)60896-3
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
resolves10.1016/S0140-6736(06)69446-4
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
resolves10.1016/S0140-6736(07)61865-0
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
resolves10.1016/j.breast.2010.11.002
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues
resolves10.1200/JCO.2000.18.22.3758
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
resolves10.1136/bmj.303.6800.435
Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.
resolves10.1093/jnci/85.17.1398
Cardiac and Thromboembolic Morbidity Among Postmenopausal Women With Early Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen
resolves10.1093/jnci/djr242
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
resolves10.1093/jnci/90.18.1371
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
resolves10.1001/jama.295.23.joc60074
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>
resolves10.1038/sj.leu.2405062
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
resolves10.1182/blood-2004-08-3231
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
resolves10.7326/0003-4819-133-11-200012050-00012
Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia
resolves10.1200/JCO.2001.19.18.3852
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
resolves10.1111/j.1540-8159.1999.tb06826.x
Complete Atrioventricular Block after Arsenic Trioxide Treatment in an Acute Promyelocytic Leukemic Patient
resolves10.1182/blood.V98.2.266
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
resolves10.1001/jama.1993.03510160067031
Factors Affecting Late Mortality From Heart Disease After Treatment of Hodgkin's Disease
resolves10.1016/j.ijrobp.2009.09.064
Radiation-Related Heart Disease: Current Knowledge and Future Prospects
resolves10.1200/JCO.2007.10.9777
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
resolves10.1093/ejechocard/jen174
European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies
resolves10.1093/ehjci/jer316
EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography
resolves10.1016/S0002-9149(03)00546-0
Echocardiographic features of Radiation-Associated valvular disease
resolves10.1016/j.echo.2013.07.005
Expert Consensus for Multi-Modality Imaging Evaluation of Cardiovascular Complications of Radiotherapy in Adults: A Report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography
resolves10.1056/NEJMoa1111961
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
resolves10.1093/jnci/djk064
Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer
resolves10.1016/j.euje.2005.04.009
Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study
resolves10.1046/j.1540-8167.2004.03625.x
Differences in Tachyarrhythmia Detection and Implantable Cardioverter Defibrillator Therapy by Primary or Secondary Prevention Indication in Cardiac Resynchronization Therapy Patients
resolves10.1016/j.echo.2013.03.014
Comprehensive Analysis of Left Ventricular Geometry and Function by Three-Dimensional Echocardiography in Healthy Adults
resolves10.1097/HJR.0b013e328012c380
Rationale, design, methods and baseline characteristics of the Asklepios Study
resolves10.1161/CIRCHEARTFAILURE.108.822627
Prevalence of Left Ventricular Diastolic Dysfunction in a General Population
resolves10.1016/0895-4356(88)90080-7
Cardia: study design, recruitment, and some characteristics of the examined subjects
resolves10.1093/ehjci/jet008
Normal Reference Ranges for Echocardiography: rationale, study design, and methodology (NORRE Study)
resolves10.1016/S1525-2167(03)00017-9
Repetitive Dobutamine Stress Echocardiography for the Prediction of Anthracycline Cardiotoxicity
resolves10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K
Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease.Clinical evaluation with special reference to childhood leukemia
resolves10.1056/NEJM197902083000603
Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography
resolves10.1056/NEJMoa032566
Diastolic Heart Failure — Abnormalities in Active Relaxation and Passive Stiffness of the Left Ventricle
resolves10.1016/S0894-7317(97)70090-7
Noninvasive Doppler-derived myocardial performance index: Correlation with simultaneous measurements of cardiac catheterization measurements
resolves10.1016/S0002-9149(98)00559-1
Prognostic value of a doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy
resolves10.1016/S0002-9149(98)00140-4
Value of a Doppler-Derived Index Combining Systolic and Diastolic Time Intervals in Predicting Outcome in Primary Pulmonary Hypertension
resolves10.1016/0735-1097(96)00202-1
Doppler index combining systolic and diastolic myocardial performance: Clinical value in cardiac amyloidisis
resolves10.1002/pbc.21289
Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia
resolves10.1016/j.ijcard.2005.07.029
Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity
resolves10.1016/j.echo.2010.02.015
Assessment of Myocardial Mechanics Using Speckle Tracking Echocardiography: Fundamentals and Clinical Applications
resolves10.1093/eurheartj/ehn484
Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging
resolves10.1016/j.jacc.2014.01.073
Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy
resolves10.1111/j.1540-8175.2011.01645.x
Trastuzumab‐Induced Cardiotoxicity: The Role of Two‐Dimensional Myocardial Strain Imaging in Diagnosis and Management
resolves10.1111/j.1540-8175.2011.01429.x
Left Ventricular Twisting and Untwisting Motion in Childhood Cancer Survivors
resolves10.1161/CIRCIMAGING.112.973321
Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
resolves10.1016/j.echo.2013.02.008
Independent and Incremental Value of Deformation Indices for Prediction of Trastuzumab-Induced Cardiotoxicity
resolves10.1161/CIRCIMAGING.109.862334
Prediction of All-Cause Mortality From Global Longitudinal Speckle Strain
resolves10.1016/j.jacc.2009.04.061
Global 2-Dimensional Strain as a New Prognosticator in Patients With Heart Failure
resolves10.1016/j.ahj.2011.10.018
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
resolves10.1093/eurjhf/hfq213
Cardiovascular Side Effects of Cancer Therapies: A Position Statement from the Heart Failure Association of the European Society of Cardiology
resolves10.1016/j.echo.2012.08.007
Variability of Global Left Ventricular Deformation Analysis Using Vendor Dependent and Independent Two-Dimensional Speckle-Tracking Software in Adults
resolves10.1161/01.CIR.0000130926.51766.CC
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
resolves10.1093/eurheartj/ehm311
Radiotherapy effects on systolic myocardial function detected by strain rate imaging in a left-breast cancer patient
resolves10.1161/01.CIR.0000130845.38133.8F
Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction
resolves10.1038/sj.bjc.6600346
Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients
resolves10.1097/MNM.0b013e32835ae523
I-123-MIBG myocardial imaging in trastuzumab-based cardiotoxicity
resolves10.1002/1097-0142(19840415)53:8<1667::AID-CNCR2820530808>3.0.CO;2-D
Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity
resolves10.1007/BF00175059
Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies
resolves10.1097/00006231-200209000-00011
High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction
resolves10.2310/7290.2008.00015
Detection of Dose Response in Chronic Doxorubicin-Mediated Cell Death with Cardiac Technetium 99m Annexin V Single-Photon Emission Computed Tomography
resolves10.1007/BF03164994
Noninvasive identification of anthracycline cardiotoxicity: Comparison of123I-MIBG and123I-BMIPP imaging
resolves10.1007/BF03006439
Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: Comparative study with myocardial perfusion, left ventricular function, and histopathological findings
resolves10.1016/j.ejca.2007.06.024
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
resolves10.1124/mi.5.3.6
The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE
resolves10.4329/wjr.v4.i5.220
Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: Evidence of early chemotherapeutic cardiotoxicity?
resolves10.1016/j.ijrobp.2006.06.007
The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage
resolves10.1007/s12350-009-9190-x
Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity
resolves10.1016/j.nucmedbio.2014.08.006
[11C]-Acetoacetate PET imaging: a potential early marker for cardiac heart failure
resolves10.1186/1532-429X-15-89
Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients
resolves10.1016/j.jacc.2006.07.003
ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 Appropriateness Criteria for Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging⁎⁎Developed in accordance with the principles and methodology outlined by ACCF: Patel MR, Spertus JA, Brindis RG, Hendel RC, Douglas PS, Peterson ED, Wolk MJ, Allen JM, Raskin IE. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol 2005;46:1606–13.
resolves10.1016/S0140-6736(11)61335-4
Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial
resolves10.1081/JCMR-200038581
Clinical Indications for Cardiovascular Magnetic Resonance (CMR): Consensus Panel Report #
resolves10.1161/hc0202.102123
Assessment of Myocardial Viability With Contrast-Enhanced Magnetic Resonance Imaging
resolves10.1016/j.echo.2014.07.012
Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
resolves10.1016/j.jacc.2010.11.063
The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy
resolves10.1186/1532-429X-15-66
Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance
resolves10.1002/pbc.22664
Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies
resolves10.1093/toxsci/kfu057
An Integrated Characterization of Serological, Pathological, and Functional Events in Doxorubicin-Induced Cardiotoxicity
resolves10.1056/NEJM200011163432003
The Use of Contrast-Enhanced Magnetic Resonance Imaging to Identify Reversible Myocardial Dysfunction
resolves10.1161/CIRCIMAGING.109.918540
Novel Approach to Early Detection of Doxorubicin Cardiotoxicity by Gadolinium-Enhanced Cardiovascular Magnetic Resonance Imaging in an Experimental Model
resolves10.1161/CIRCIMAGING.114.002217
Longitudinal Assessment of Concurrent Changes in Left Ventricular Ejection Fraction and Left Ventricular Myocardial Tissue Characteristics After Administration of Cardiotoxic Chemotherapies Using T1-Weighted and T2-Weighted Cardiovascular Magnetic Resonance
resolves10.1148/radiol.2382041903
Human Myocardium: Single-Breath-hold MR T1 Mapping with High Spatial Resolution—Reproducibility Study
resolves10.1148/radiol.2502080498
Nephrogenic Systemic Fibrosis: Incidence, Associations, and Effect of Risk Factor Assessment—Report of 33 Cases
resolves10.1046/j.1365-2796.2001.00820.x
Comparison of echocardiography and radionuclide ventriculography in the follow‐up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy
The 11 references without a DOI — listed, not checked
no DOI — not checkedPharmacokinetics and metabolism of anthracyclines
no DOI — not checkedIn vitro evidence that myocardial ischemia resulting from 5‐fluorouracil chemotherapy is due to protein kinase C‐mediated vasoconstriction of vascular smooth muscle
no DOI — not checkedCapecitabine‐related cardiotoxicity: recognition and management
no DOI — not checkedA reassessment of cardiac toxicity associated with Taxol
no DOI — not checkedA detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one‐ or three‐hour‐infusion paclitaxel in patients with metastatic breast cancer
no DOI — not checkedVindesine‐associated angina and ECG changes
no DOI — not checkedClinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
no DOI — not checkedNew non‐invasive index for combined systolic and diastolic ventricular function
no DOI — not checkedModern nuclear cardiac imaging in diagnosis and clinical management of patients with left ventricular dysfunction
no DOI — not checkedMetaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy
no DOI — not checkedNon‐invasive monitoring of cardiac hemodynamic parameters in doxorubicin‐treated patients: comparison with echocardiography
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1111/eci.12589"><img src="https://citestamp.com/citestamped/10.1111/eci.12589/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1111/eci.12589)